Antiproliferative and Antiangiogenic Properties of New VEGFR-2-targeting 2-thioxobenzogquinazoline Derivatives (In Vitro)
A series of 3-ethyl(methyl)-2-thioxo-2,3-dihydrobenzo[g]quinazolines (1-17) were synthesized, characterized, and evaluated in vitro for their antiangiogenesis VEGFR-2-targeting, antiproliferative, and antiapoptotic activities against breast MCF-7 and liver HepG2 cells. Flow cytometry was used to det...
Saved in:
Published in | Molecules (Basel, Switzerland) Vol. 25; no. 24 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
15.12.2020
|
Online Access | Get full text |
Cover
Loading…
Abstract | A series of 3-ethyl(methyl)-2-thioxo-2,3-dihydrobenzo[g]quinazolines (1-17) were synthesized, characterized, and evaluated in vitro for their antiangiogenesis VEGFR-2-targeting, antiproliferative, and antiapoptotic activities against breast MCF-7 and liver HepG2 cells. Flow cytometry was used to determine cancer-cell cycle distributions, and apoptosis was detected using annexin-V-FITC (V) and propidium iodide (PI) dyes. Fluorescence microscopy, in combination with Hoechst staining was used to detect DNA fragmentation. Most of the tested benzo[g]quinazolines demonstrated promising activity (IC50 = 8.8 ± 0.5-10.9 ± 0.9 μM) and (IC50 = 26.0 ± 2.5-40.4 ± 4.1 μM) against MCF-7 and HepG2, respectively. Doxorubicin was used as a reference drug. Compounds 13-15 showed the highest activity against both cancer cell lines. Differential effects were detected by cell-cycle analysis, indicating similarities in the actions of 13 and 14 against both MCF7 and HepG2, involving the targeting of G1 and S phases, respectively. Compound 15 showed similar indices against both cells, indicating that its cytotoxicity toward the examined cancer cells could be unselective. Interestingly, 14 and 15 showed the highest apoptosis (30.76% and 25.30%, respectively) against MCF-7. The DNA fragmentation results agreed well with the apoptosis detected by flow cytometry. In terms of antiangiogenesis activity, as derived from VEGFR-2 inhibition, 13 and 15 were comparable to sorafenib and effected 1.5- and 1.4-fold inhibition relative to the standard sorafenib. A docking study was conducted to investigate the interaction between the synthesized benzo[g]quinazolines and the ATP-binding site within the catalytic domain of VEGFR-2.A series of 3-ethyl(methyl)-2-thioxo-2,3-dihydrobenzo[g]quinazolines (1-17) were synthesized, characterized, and evaluated in vitro for their antiangiogenesis VEGFR-2-targeting, antiproliferative, and antiapoptotic activities against breast MCF-7 and liver HepG2 cells. Flow cytometry was used to determine cancer-cell cycle distributions, and apoptosis was detected using annexin-V-FITC (V) and propidium iodide (PI) dyes. Fluorescence microscopy, in combination with Hoechst staining was used to detect DNA fragmentation. Most of the tested benzo[g]quinazolines demonstrated promising activity (IC50 = 8.8 ± 0.5-10.9 ± 0.9 μM) and (IC50 = 26.0 ± 2.5-40.4 ± 4.1 μM) against MCF-7 and HepG2, respectively. Doxorubicin was used as a reference drug. Compounds 13-15 showed the highest activity against both cancer cell lines. Differential effects were detected by cell-cycle analysis, indicating similarities in the actions of 13 and 14 against both MCF7 and HepG2, involving the targeting of G1 and S phases, respectively. Compound 15 showed similar indices against both cells, indicating that its cytotoxicity toward the examined cancer cells could be unselective. Interestingly, 14 and 15 showed the highest apoptosis (30.76% and 25.30%, respectively) against MCF-7. The DNA fragmentation results agreed well with the apoptosis detected by flow cytometry. In terms of antiangiogenesis activity, as derived from VEGFR-2 inhibition, 13 and 15 were comparable to sorafenib and effected 1.5- and 1.4-fold inhibition relative to the standard sorafenib. A docking study was conducted to investigate the interaction between the synthesized benzo[g]quinazolines and the ATP-binding site within the catalytic domain of VEGFR-2. |
---|---|
AbstractList | A series of 3-ethyl(methyl)-2-thioxo-2,3-dihydrobenzo[g]quinazolines (1-17) were synthesized, characterized, and evaluated in vitro for their antiangiogenesis VEGFR-2-targeting, antiproliferative, and antiapoptotic activities against breast MCF-7 and liver HepG2 cells. Flow cytometry was used to determine cancer-cell cycle distributions, and apoptosis was detected using annexin-V-FITC (V) and propidium iodide (PI) dyes. Fluorescence microscopy, in combination with Hoechst staining was used to detect DNA fragmentation. Most of the tested benzo[g]quinazolines demonstrated promising activity (IC50 = 8.8 ± 0.5-10.9 ± 0.9 μM) and (IC50 = 26.0 ± 2.5-40.4 ± 4.1 μM) against MCF-7 and HepG2, respectively. Doxorubicin was used as a reference drug. Compounds 13-15 showed the highest activity against both cancer cell lines. Differential effects were detected by cell-cycle analysis, indicating similarities in the actions of 13 and 14 against both MCF7 and HepG2, involving the targeting of G1 and S phases, respectively. Compound 15 showed similar indices against both cells, indicating that its cytotoxicity toward the examined cancer cells could be unselective. Interestingly, 14 and 15 showed the highest apoptosis (30.76% and 25.30%, respectively) against MCF-7. The DNA fragmentation results agreed well with the apoptosis detected by flow cytometry. In terms of antiangiogenesis activity, as derived from VEGFR-2 inhibition, 13 and 15 were comparable to sorafenib and effected 1.5- and 1.4-fold inhibition relative to the standard sorafenib. A docking study was conducted to investigate the interaction between the synthesized benzo[g]quinazolines and the ATP-binding site within the catalytic domain of VEGFR-2.A series of 3-ethyl(methyl)-2-thioxo-2,3-dihydrobenzo[g]quinazolines (1-17) were synthesized, characterized, and evaluated in vitro for their antiangiogenesis VEGFR-2-targeting, antiproliferative, and antiapoptotic activities against breast MCF-7 and liver HepG2 cells. Flow cytometry was used to determine cancer-cell cycle distributions, and apoptosis was detected using annexin-V-FITC (V) and propidium iodide (PI) dyes. Fluorescence microscopy, in combination with Hoechst staining was used to detect DNA fragmentation. Most of the tested benzo[g]quinazolines demonstrated promising activity (IC50 = 8.8 ± 0.5-10.9 ± 0.9 μM) and (IC50 = 26.0 ± 2.5-40.4 ± 4.1 μM) against MCF-7 and HepG2, respectively. Doxorubicin was used as a reference drug. Compounds 13-15 showed the highest activity against both cancer cell lines. Differential effects were detected by cell-cycle analysis, indicating similarities in the actions of 13 and 14 against both MCF7 and HepG2, involving the targeting of G1 and S phases, respectively. Compound 15 showed similar indices against both cells, indicating that its cytotoxicity toward the examined cancer cells could be unselective. Interestingly, 14 and 15 showed the highest apoptosis (30.76% and 25.30%, respectively) against MCF-7. The DNA fragmentation results agreed well with the apoptosis detected by flow cytometry. In terms of antiangiogenesis activity, as derived from VEGFR-2 inhibition, 13 and 15 were comparable to sorafenib and effected 1.5- and 1.4-fold inhibition relative to the standard sorafenib. A docking study was conducted to investigate the interaction between the synthesized benzo[g]quinazolines and the ATP-binding site within the catalytic domain of VEGFR-2. |
Author | Abuelizz, Hatem A Awad, Hanem M Naglah, Ahmed M Soltan, Maha M Al-Salahi, Rashad Marzouk, Mohamed Bakheit, Ahmed H |
Author_xml | – sequence: 1 givenname: Hatem A surname: Abuelizz fullname: Abuelizz, Hatem A – sequence: 2 givenname: Mohamed surname: Marzouk fullname: Marzouk, Mohamed – sequence: 3 givenname: Ahmed H surname: Bakheit fullname: Bakheit, Ahmed H – sequence: 4 givenname: Hanem M surname: Awad fullname: Awad, Hanem M – sequence: 5 givenname: Maha M surname: Soltan fullname: Soltan, Maha M – sequence: 6 givenname: Ahmed M surname: Naglah fullname: Naglah, Ahmed M – sequence: 7 givenname: Rashad surname: Al-Salahi fullname: Al-Salahi, Rashad |
BookMark | eNqVjj1PAzEQRC0UJJLAD6BzGYoDfx1wJYIEaCKEUNrIHHvHImc3sX0B8us5EAUt1TyNRk8zEgNiAiGOtTq1tlJnKw5QdwGSKY0rK-f2xFA7owqrXDX4wwdilNKbUkY7XQ7F5xVlXEcO2ED0GbcgPb3I79ZTi9wCYS0fIq8hZoQkuZFzeJeL6e3ssTBF9rGFjNTKnl-RP_gZaMftpkPyu15LIG8g4vbHneTknuQCc-STQ7Hf-JDg6DfHYjKbPl3fFf2bTQcpL1eYagjBE3CXlsZdaHduS3tp_zH9Agn-XEc |
ContentType | Journal Article |
DBID | 7X8 |
DOI | 10.3390/molecules25245944 |
DatabaseName | MEDLINE - Academic |
DatabaseTitle | MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry |
EISSN | 1420-3049 |
GroupedDBID | --- 0R~ 123 2WC 3V. 53G 5VS 7X7 7X8 88E 8FE 8FG 8FH 8FI 8FJ A8Z AADQD AAFWJ AAHBH ABDBF ABJCF ABUWG ACGFO ACIWK ACPRK AEGXH AENEX AFKRA AFPKN AFRAH AFZYC AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS BBNVY BENPR BHPHI BPHCQ BVXVI CCPQU CS3 D1I DIK DU5 E3Z EBD EMOBN ESTFP ESX FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE HZ~ I09 KB. KQ8 LK8 M1P M7P MODMG M~E O-U O9- OK1 P2P PDBOC PIMPY PQQKQ PROAC PSQYO RIG RPM SV3 TR2 TUS UKHRP ~8M |
ID | FETCH-proquest_miscellaneous_24714635383 |
ISSN | 1420-3049 |
IngestDate | Fri Jul 26 19:11:17 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 24 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-proquest_miscellaneous_24714635383 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 content type line 23 ObjectType-Feature-2 |
PQID | 2471463538 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_2471463538 |
PublicationCentury | 2000 |
PublicationDate | 20201215 |
PublicationDateYYYYMMDD | 2020-12-15 |
PublicationDate_xml | – month: 12 year: 2020 text: 20201215 day: 15 |
PublicationDecade | 2020 |
PublicationTitle | Molecules (Basel, Switzerland) |
PublicationYear | 2020 |
SSID | ssj0021415 |
Score | 4.683109 |
Snippet | A series of 3-ethyl(methyl)-2-thioxo-2,3-dihydrobenzo[g]quinazolines (1-17) were synthesized, characterized, and evaluated in vitro for their antiangiogenesis... |
SourceID | proquest |
SourceType | Aggregation Database |
Title | Antiproliferative and Antiangiogenic Properties of New VEGFR-2-targeting 2-thioxobenzogquinazoline Derivatives (In Vitro) |
URI | https://www.proquest.com/docview/2471463538/abstract/ |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1BT9swFLYKHLYLGmPTNkblSTuAUNiaxE1ybLuWMpEysYJ6q-zi0AhqQ5eskCO_nGc7bcMKgnGxIitxnLxP9vPn9z0j9JVz8PEdymD0c6jlukFk-dVKZFUcRviAEd-LlBo57FTbx-7PHumVSreFqKU0YbuD7EFdyUusCnVgV6WS_Q_LzhqFCrgG-0IJFobyWTauiSS-VMfuRDxP4K1ocFVLxVks4TkV-K7o9rHKm6rZAT7ZOWnutY4s2zJR4IorgOthLK8l4yKTZ1dpLGgmtQP6A77jr25b07P7YuckTpQ2Jii6taE5ZNfcU4eJURPLvydxkhk1cZFwYCm_iDNNXLfB0x3N6dSQjjOZ6vE5lEM6yoVXmmg9H_LYpEgYQv1cU1GbGJC2qYCmwiKLYeuIEKPjzAdeVym5v5v0pbv8gbp8tLZJAZVGfv3vLOA4gQqbHE0_3Sa2SwKTZvJ-xu3OYb91fHDQ7zZ73SW0YnsBgQX8Sr3Z-XU0W7ZXXH0Oxqw3Zm9cveTbwisWZnTtpnTfoNV8fYFrBixrqMTFW_SqMT3Wbx3dLIAGg33wfdDgOWiwjDCABi-ABj8KGlwADd7aF1hDZvsd2mo1u422Ne17H_qkNo7AcjL907fBg3HBM3V85z1aFlLwDwgH3iljhPgs8JkbVAa0yiLKPfhB9qn6ax_Rlyeb-_SMezbQ6zlgPqPlZJzyTXAEE1ZGS17Pg9Jv7ZVzq5U1qXIHZ0ts-A |
link.rule.ids | 315,786,790,870,27957,27958,31755,33409,33780 |
linkProvider | ProQuest |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antiproliferative+and+Antiangiogenic+Properties+of+New+VEGFR-2-targeting+2-thioxobenzogquinazoline+Derivatives+%28In+Vitro%29&rft.jtitle=Molecules+%28Basel%2C+Switzerland%29&rft.au=Abuelizz%2C+Hatem+A&rft.au=Marzouk%2C+Mohamed&rft.au=Bakheit%2C+Ahmed+H&rft.au=Awad%2C+Hanem+M&rft.date=2020-12-15&rft.issn=1420-3049&rft.eissn=1420-3049&rft.volume=25&rft.issue=24&rft_id=info:doi/10.3390%2Fmolecules25245944&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1420-3049&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1420-3049&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1420-3049&client=summon |